Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proglumide in NASH
NCT04152473Phase 1Completed
- Sponsor
- Georgetown University
- Start
- Dec 2019
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Proglumide in Nonalcoholic steatohepatitis (NASH) (3 arms), sponsored by Georgetown University. Primary endpoints: Safety and toxicity at 12 weeks and Recommended Phase 2 dose at 12 weeks. Started Dec 2019; status: completed.
02
Drugs
Proglumide
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04152473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04152473.